# PBLS (Parabilis Medicines, Inc.) - SEC EDGAR Financial Statements

> Parabilis Medicines, Inc. reported $1.13B in total assets through September 30, 2026 from SEC EDGAR filings.

- Canonical: https://convexityos.com/fundamentals/PBLS
- Markdown: https://convexityos.com/fundamentals/PBLS.md
- SEC CIK: 0001657677
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 20, 2026, 05:18 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001657677&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2026 | -- | Sep 30, 2026 |
| Operating Income | FY 2026 | -- | Operating profit |
| Net Income | FY 2026 | -- | GAAP bottom line |
| Diluted EPS | FY 2026 | -- | Split-adjusted |
| Free Cash Flow | FY 2026 | -- | Operating CF less CapEx |
| Cash & ST Investments | Sep 30, 2026 | $871.6M | Total debt: $41.83M |

## Income Statement

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 |
| --- | --- | --- | --- | --- | --- | --- |
| **Revenue** | $2.11M | $148K | -- | $0 | $0 | -- |
| Research & Development | $45.60M | $39.38M | -- | $28.20M | $30.13M | -- |
| Total Operating Expenses | $56.85M | $51.03M | -- | $34.84M | $36.52M | -- |
| **Operating Income** | -$54.74M | -$50.89M | -- | -$34.84M | -$36.52M | -- |
| **EBITDA** | -$54.14M | -$50.29M | -- | -$34.74M | -$36.32M | -- |
| Interest Income | $10.37M | $4.19M | -- | $711K | $1.05M | -- |
| Interest Expense | $124K | $210K | -- | $398K | $396K | -- |
| **Net Income** | -$44.49M | -$52.46M | -$45.32M | -$33.48M | -$34.81M | -$38.33M |
| Basic EPS | -$0.36 | -$2.32 | -- | -$21.66 | -$22.28 | -- |
| **Diluted EPS** | -$0.36 | -$2.32 | -- | -$21.66 | -$22.28 | -- |
| Basic Shares Outstanding | 123.6M | 28.9M | -- | 2.0M | 2.0M | -- |
| Diluted Shares Outstanding | 123.6M | 28.9M | -- | 2.0M | 2.0M | -- |

## Balance Sheet

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Dec 2025 |
| --- | --- | --- | --- |
| Cash & Cash Equivalents | $521.2M | $1.09B | $27.71M |
| Short-Term Investments | $350.4M | $33.64M | $0 |
| **Cash & Short-Term Investments** | $871.6M | $1.12B | $27.71M |
| Accounts Receivable, Net | $443K | -- | $0 |
| **Total Current Assets** | $879.0M | $1.13B | $29.36M |
| Property, Plant & Equipment, Net | $9.51M | $6.72M | $6.71M |
| Long-Term Investments | $201.3M | -- | $0 |
| **Total Non-Current Assets** | $252.2M | $49.87M | $51.46M |
| **Total Assets** | $1.13B | $1.18B | $80.82M |
| Accounts Payable | $20.21M | $18.52M | $17.27M |
| Short-Term Debt | $2.00M | $5.71M | $13.08M |
| Deferred Revenue (Current) | $13.54M | $10.37M | $0 |
| **Total Current Liabilities** | $68.26M | $62.84M | $56.79M |
| Long-Term Debt | -- | $700K | $600K |
| Deferred Revenue (Non-Current) | $27.30M | $31.15M | $0 |
| **Total Non-Current Liabilities** | $58.64M | $64.69M | $40.55M |
| **Total Liabilities** | $126.9M | $127.5M | $97.34M |
| **Total Debt (incl. Leases)** | $41.83M | $48.21M | $59.30M |
| Common Stock | $12K | $12K | $0 |
| Retained Earnings | -$683.8M | -$639.3M | -$541.5M |
| Accumulated Other Comp. Income | -$1.91M | -$18K | $0 |
| **Total Stockholders' Equity** | $1.00B | $1.05B | -$526.5M |
| Total Equity | $1.00B | $1.05B | -$526.5M |

## Cash Flow Statement

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 |
| --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$44.49M | -$52.46M | -$45.32M | -$33.48M | -$34.81M | -$38.33M |
| Depreciation & Amortization | $600K | $600K | -- | $100K | $200K | -- |
| Stock-Based Compensation | $2.74M | $3.63M | -- | $820K | $823K | -- |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 |
| --- | --- | --- | --- | --- | --- | --- |
| Current Ratio | 12.88x | 17.91x | -- | -- | -- | -- |
| Quick Ratio | 12.78x | 17.83x | -- | -- | -- | -- |
| Debt to Equity | 0.04x | 0.05x | -- | -- | -- | -- |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
